Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | BET Inhibitor CPI-0610 and ruxolitinib for myelofibrosis

Srdan Verstovsek • 15 Jun 2019
EHA 2019
Myelofibrosis CPI-0610 Ruxolitinib

Here, Srdan Verstovsek, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, presents updates on the use of the BET Inhibitor CPI-0610 in combination with ruxolitinib for myelofibrosis. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Srdan Verstovsek

1:52
An update on the use of navtemadlin in myelofibrosis
Srdan Verstovsek • 7 Dec 2022
2:19
Insights into the Phase IIa Mylox-1 trial: assessing efficacy of GB2064 in myelofibrosis
Srdan Verstovsek • 7 Dec 2022
2:19
FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangement
Srdan Verstovsek • 7 Dec 2022
1:56
Rationale for VERIFY: rusfertide added to ongoing therapy in patients with polycythemia vera
Srdan Verstovsek • 7 Dec 2022

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals